Reinforcing vasal suture technique improves sperm concentration and pregnancy rates in men undergoing vasovasostomy for vasectomy reversal.

Vasectomy reversal (VR) epididymovasostomy (EV) microsurgery pregnancy vasovasostomy (VV)

Journal

Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119

Informations de publication

Date de publication:
Feb 2020
Historique:
entrez: 15 2 2020
pubmed: 15 2 2020
medline: 15 2 2020
Statut: ppublish

Résumé

Vasovasostomy (VV) is a well-described surgical technique with few notable modifications since microsurgical adaptation in the 1970s. Although contemporary reversal success rates are 70-90%, these most often are based on a lenient definition of >0 sperm (patency) and include only VV procedures. With stricter definitions, success rates drop >30%. To improve outcomes, a novel surgical technique (reinforcing vasal suture, ReVas) was developed, and outcomes were compared prior to and following implementation. A prospective registry of sequential patients undergoing vasectomy reversal was queried from Jan 2014 to June 2019. The ReVas technique was implemented in Jan 2018, wherein the abdominal and testicular vasa are secured side-to-side to alleviate strain on the anastomosis. Primary outcomes were changes in sperm concentration: >0/mL, >100,000/mL, >1 million/mL, >5 million/mL, >15 million/mL, and most recent. Secondary outcome was pregnancy rate. Demographic, clinical, and select operative variables were statistically compared between ReVas (+) and (-) cohorts. A total of 200 men underwent reversal, of whom 169 represented first-time attempts (61 receiving the new technique) and comprise the current cohort. ReVas (+) and (-) cohorts were similar in demographic, clinical, and operative factors with the exception of operative time [longer in ReVas (+) group]. Median duration since vasectomy was 9 years, and 68.6% of men received a bilateral VV. Follow-up was significantly longer in the ReVas (-) arm (37 Implementation of the ReVas technique resulted in significantly higher sperm concentrations, which were particularly pronounced when stricter success criteria were used. Patients were also 8.1× more likely to achieve a pregnancy within the first 2 years, confirming clinical relevance. External validation is warranted.

Sections du résumé

BACKGROUND BACKGROUND
Vasovasostomy (VV) is a well-described surgical technique with few notable modifications since microsurgical adaptation in the 1970s. Although contemporary reversal success rates are 70-90%, these most often are based on a lenient definition of >0 sperm (patency) and include only VV procedures. With stricter definitions, success rates drop >30%. To improve outcomes, a novel surgical technique (reinforcing vasal suture, ReVas) was developed, and outcomes were compared prior to and following implementation.
METHODS METHODS
A prospective registry of sequential patients undergoing vasectomy reversal was queried from Jan 2014 to June 2019. The ReVas technique was implemented in Jan 2018, wherein the abdominal and testicular vasa are secured side-to-side to alleviate strain on the anastomosis. Primary outcomes were changes in sperm concentration: >0/mL, >100,000/mL, >1 million/mL, >5 million/mL, >15 million/mL, and most recent. Secondary outcome was pregnancy rate. Demographic, clinical, and select operative variables were statistically compared between ReVas (+) and (-) cohorts.
RESULTS RESULTS
A total of 200 men underwent reversal, of whom 169 represented first-time attempts (61 receiving the new technique) and comprise the current cohort. ReVas (+) and (-) cohorts were similar in demographic, clinical, and operative factors with the exception of operative time [longer in ReVas (+) group]. Median duration since vasectomy was 9 years, and 68.6% of men received a bilateral VV. Follow-up was significantly longer in the ReVas (-) arm (37
CONCLUSIONS CONCLUSIONS
Implementation of the ReVas technique resulted in significantly higher sperm concentrations, which were particularly pronounced when stricter success criteria were used. Patients were also 8.1× more likely to achieve a pregnancy within the first 2 years, confirming clinical relevance. External validation is warranted.

Identifiants

pubmed: 32055470
doi: 10.21037/tau.2019.09.41
pii: tau-09-01-73
pmc: PMC6995932
doi:

Types de publication

Journal Article

Langues

eng

Pagination

73-81

Informations de copyright

2020 Translational Andrology and Urology. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors have no conflicts of interest to declare.

Références

J Urol. 2008 Jan;179(1):256-9
pubmed: 18001786
Transl Androl Urol. 2017 Aug;6(4):761-772
pubmed: 28904909
Fertil Steril. 2017 Apr;107(4):911-915
pubmed: 28283266
Urol Clin North Am. 2009 Aug;36(3):375-82
pubmed: 19643239
J Urol. 1991 Mar;145(3):505-11
pubmed: 1997700
World J Mens Health. 2017 Aug;35(2):115-119
pubmed: 28868820
Urology. 2015 Apr;85(4):819-25
pubmed: 25817104
J Urol. 1973 Nov;110(5):556-7
pubmed: 4750901
Reprod Med Biol. 2018 May 22;17(4):343-355
pubmed: 30377390
J Urol. 2019 Feb;201(2):241-250
pubmed: 30130545
J Robot Surg. 2019 Jun;13(3):501-504
pubmed: 30382458
Fertil Steril. 1977 Nov;28(11):1191-202
pubmed: 923835
Int J Androl. 1991 Feb;14(1):1-10
pubmed: 2007522

Auteurs

Joshua Savage (J)

Male Fertility and Peyronie's Clinic, Orem, UT, USA.

Madeleine Manka (M)

Mayo Clinic, Rochester, MN, USA.

Tiffany Rindels (T)

Mayo Clinic, Rochester, MN, USA.

Manaf Alom (M)

Mayo Clinic, Rochester, MN, USA.

Kiran L Sharma (KL)

Mayo Clinic, Rochester, MN, USA.

Landon Trost (L)

Male Fertility and Peyronie's Clinic, Orem, UT, USA.

Classifications MeSH